292 related articles for article (PubMed ID: 15478063)
41. Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients.
Görzer I; Puchhammer-Stöckl E; van Esser JW; Niesters HG; Cornelissen JJ
Clin Infect Dis; 2007 Mar; 44(5):693-5. PubMed ID: 17278061
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
43. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
[TBL] [Abstract][Full Text] [Related]
44. Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort.
Baiocchi OC; Colleoni GW; Caballero OL; Vettore AL; Andrade AL; Pestana JO
Haematologica; 2004 Mar; 89(3):366-8. PubMed ID: 15020282
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
46. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
47. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.
Heslop HE
J Immunother; 2001; 24(4):283-4. PubMed ID: 11565828
[No Abstract] [Full Text] [Related]
48. Adequate control of primary EBV infection and subsequent reactivations after cardiac transplantation in an EBV seronegative patient.
Pietersma FL; van Oosterom A; Ran L; Schuurman R; Meijer E; de Jonge N; van Baarle D
Transpl Immunol; 2012 Aug; 27(1):48-51. PubMed ID: 22342937
[TBL] [Abstract][Full Text] [Related]
49. Depletion of EBV-infected cells in donor marrow by counterflow elutriation.
Gross TG; Hinrichs SH; Davis JR; Mitchell D; Bishop MR; Wagner JE
Exp Hematol; 1998 May; 26(5):395-9. PubMed ID: 9590655
[TBL] [Abstract][Full Text] [Related]
50. Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load.
Zawilinska B; Kosinska A; Lenart M; Kopec J; Piatkowska-Jakubas B; Skotnicki A; Kosz-Vnenchak M
Acta Biochim Pol; 2008; 55(4):693-9. PubMed ID: 19015775
[TBL] [Abstract][Full Text] [Related]
51. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
Guppy AE; Rawlings E; Madrigal JA; Amlot PL; Barber LD
Transplantation; 2007 Dec; 84(11):1534-9. PubMed ID: 18091531
[TBL] [Abstract][Full Text] [Related]
52. The impact of EBV load on T-cell immunity in pediatric thoracic transplant recipients.
Macedo C; Zeevi A; Bentlejewski C; Popescu I; Green M; Rowe D; Smith L; Webber S; Metes D
Transplantation; 2009 Jul; 88(1):123-8. PubMed ID: 19584691
[TBL] [Abstract][Full Text] [Related]
53. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
54. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
55. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
[TBL] [Abstract][Full Text] [Related]
56. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder.
Kuzushima K; Kimura H; Hoshino Y; Yoshimi A; Tsuge I; Horibe K; Morishima T; Tsurumi T; Kojima S
J Infect Dis; 2000 Sep; 182(3):937-40. PubMed ID: 10950793
[TBL] [Abstract][Full Text] [Related]
57. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.
Meijer E; Slaper-Cortenbach IC; Thijsen SF; Dekker AW; Verdonck LF
Bone Marrow Transplant; 2002 Feb; 29(4):335-9. PubMed ID: 11896431
[TBL] [Abstract][Full Text] [Related]
58. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
[TBL] [Abstract][Full Text] [Related]
59. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection.
Bauer CC; Aberle SW; Popow-Kraupp T; Kapitan M; Hofmann H; Puchhammer-Stöckl E
J Med Virol; 2005 Jan; 75(1):54-8. PubMed ID: 15543583
[TBL] [Abstract][Full Text] [Related]
60. Epstein-Barr virus-associated lymphoproliferative disorders.
Ambinder RF
Rev Clin Exp Hematol; 2003 Dec; 7(4):362-74. PubMed ID: 15129648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
